Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has demonstrated increased efficacy with its latest, patented, licensed, anti-cancer drug, TLD-1633, when compared to its lead anti-cancer drug, TLD-1433.

 

The latest PDC, known as TLD-1633, has recently been shown to be approximately 15% more effective than TLD-1433 in the destruction of a human Glioblastoma Multiforme (“GBM”) cell line (U87), a deadly form of brain cancer.

 

In preclinical research, TLD-1633 has also demonstrated a lower dark toxicity, supporting an even higher safety profile than TLD-1433.

 

To view the graphic in its original size, please click here

 

To view the graphic in its original size, please click here

 

TLD-1633 Photo Dynamic Therapy (“PDT”) when activated by green laser light (530 nm, 90 J/cm2) and dark toxicity (no laser light) compared to TLD-1433 in U87 GBM cells.

 

Pavel Kaspler, Ph.D., a research scientist at Theralase stated that, “Research on Theralase’s latest licensed anti-cancer drug, TLD-1633, is showing even stronger data preclinically than Theralase’s top performing anti-cancer drug TLD-1433. I look forward to expanding my research to assess the performance of TLD-1633 in various cancer lines, with and without the use of transferrin, as a transport system.”

 

Sherri McFarland, Ph.D., Professor, Department of Chemistry and Biochemistry, The University of North Carolina at Greensboro stated that, “TLD-1633 is a natural progression of the research work completed by our research labs in the development of TLD-1433. TLD-1633 has shown even stronger safety and efficacy in our labs than TLD-1433, and I am delighted to work with Theralase to optimize and expand their licenced PDC program, as we embark on additional cancer indications.”

 

Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer of Theralase stated that, “I am delighted that TLD-1633 has been added to our growing list of compounds, identified by Dr. McFarland’s research program, in conjunction with our own, as potent anti-cancer agents. TLD-1433 was originally chosen as the lead anti-cancer PDC in our fight against Non-Muscle Invasive Bladder Cancer (“NMIBC”), because of its strong characteristics, but it seems an even more potent PDC, TLD-1633, may be better suited to be utilized for other cancers of the body, such as GBM, especially when combined with transferrin. This is truly ground-breaking research that myself and the entire Theralase research team are delighted to be involved with.”

 

Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase continues to expand our preclinical research and development, both in bringing new PDCs on-line and investigating new clinical applications, that we hope to translate into new clinical programs, in the not too distant future, via Phase Ib clinical studies.”

 

About Theralase Technologies Inc.

 

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

 

Additional information is available at www.theralase.com and www.sedar.com.

 

This news release contains "forward-looking statements" which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as "may", "would", "could", “should”, "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

 

For More Information:

Roger Dumoulin-White

President & CEO

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225

rwhite@theralase.com

www.theralase.com

To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/Theralase09122017.pdf

Source: Theralase Technologies Inc. (TSX Venture:TLT, OTCQX:TLTFF)

To follow Theralase Technologies Inc. on your favorite social media platform or financial websites, please click on the icons below.

 

Maximum News Dissemination by FSCwire. http://www.fscwire.com

 

Copyright © 2017 Filing Services Canada Inc.